NervGen Pharma Management

Management criteria checks 1/4

NervGen Pharma's CEO is Mike Kelly, appointed in Apr 2023, has a tenure of 1.5 years. total yearly compensation is CA$740.33K, comprised of 72.9% salary and 27.1% bonuses, including company stock and options. directly owns 0.21% of the company’s shares, worth CA$348.37K. The average tenure of the management team and the board of directors is 1.5 years and 3.8 years respectively.

Key information

Mike Kelly

Chief executive officer

CA$740.3k

Total compensation

CEO salary percentage	72.9%
CEO tenure	1.5yrs
CEO ownership	0.2%
Management average tenure	1.5yrs
Board average tenure	3.8yrs

Recent management updates

Recent updates

We're Interested To See How NervGen Pharma (CVE:NGEN) Uses Its Cash Hoard To Grow

Jun 11

NervGen Pharma Corp. (CVE:NGEN) Shares Could Be 31% Below Their Intrinsic Value Estimate

Feb 02

We're Keeping An Eye On NervGen Pharma's (CVE:NGEN) Cash Burn Rate

Nov 23

We Think NervGen Pharma (CVE:NGEN) Needs To Drive Business Growth Carefully

Jun 29

We're Not Very Worried About NervGen Pharma's (CVE:NGEN) Cash Burn Rate

Mar 16

We're Keeping An Eye On NervGen Pharma's (CVE:NGEN) Cash Burn Rate

Mar 08

CEO Compensation Analysis

How has Mike Kelly's remuneration changed compared to NervGen Pharma's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	-CA$23m
Mar 31 2024	n/a	n/a	-CA$20m
Dec 31 2023	CA$740k	CA$540k	-CA$22m

Compensation vs Market: Mike's total compensation ($USD548.49K) is above average for companies of similar size in the Canadian market ($USD177.89K).

Compensation vs Earnings: Insufficient data to compare Mike's compensation with company performance.

CEO

Mike Kelly (58 yo)

1.5yrs

Tenure

CA$740,330

Compensation

Mr. Michael Kelly, also known as Mike, is an Independent Director of ARS Pharmaceuticals, Inc. and joined in May 2019. He serves as Chief Executive Officer, President and Director of NervGen Pharma Corp. s...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Michael Kelly	CEO, President & Director	1.5yrs	CA$740.33k	0.21% CA$ 348.4k
William Radvak	Co-Founder & Advisor	no data	CA$60.00k	0% CA$ 0
Harold Punnett	Co-Founder & Independent Director	no data	no data	1.6% CA$ 2.7m
William Adams	CFO & Corporate Secretary	4.7yrs	CA$431.63k	0.22% CA$ 377.1k
Daniel Mikol	Chief Medical Officer	3.4yrs	CA$793.99k	no data
Brian McAlister	Co-Founder & Advisor	no data	no data	no data
Charles Olson	Senior Vice President of Technical Operations	less than a year	no data	no data
Elizabeth Eberhardt	Senior Vice President of Program Management	less than a year	no data	no data

1.5yrs

Average Tenure

61.5yo

Average Age

Experienced Management: NGEN's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Michael Kelly	CEO, President & Director	1.5yrs	CA$740.33k	0.21% CA$ 348.4k
Harold Punnett	Co-Founder & Independent Director	7.8yrs	no data	1.6% CA$ 2.7m
Brian McAlister	Co-Founder & Advisor	no data	no data	no data
Glenn Ives	Chairman	3.1yrs	no data	0.083% CA$ 141.6k
Brian Bayley	Independent Director	6.4yrs	no data	0.57% CA$ 968.0k
Randall Kaye	Independent Director	4yrs	no data	0.014% CA$ 24.2k
Jeffrey Cummings	Member of Alzheimer's Disease Scientific Advisory Board	3.8yrs	no data	no data
Jerry Silver	Co-Inventor & Scientific Advisor	no data	no data	no data
George Perry	Member of Alzheimer's Disease Scientific Advisory Board	3.8yrs	no data	no data
Henrik Zetterberg	Member of Alzheimer's Disease Scientific Advisory Board	3.8yrs	no data	no data
Michael Davis	Advisor	4yrs	no data	no data
Bruce Lamb	Member of Alzheimer's Disease Scientific Advisory Board	3.8yrs	no data	no data

3.8yrs

Average Tenure

66.5yo

Average Age

Experienced Board: NGEN's board of directors are considered experienced (3.8 years average tenure).

NervGen Pharma Management

Management criteria checks 1/4

Key information

Recent management updates

Insufficient new directors

NervGen Pharma Corp. Appoints Neil Klompas to Board of Directors

Insufficient new directors

NervGen Pharma Corp. Approves Board and Audit Committee Elections

CEO, President & Director recently bought CA$338k worth of stock

NervGen Pharma Corp., Annual General Meeting, Jun 04, 2024

Recent updates

Insufficient new directors

NervGen Pharma Corp. Appoints Neil Klompas to Board of Directors

We're Interested To See How NervGen Pharma (CVE:NGEN) Uses Its Cash Hoard To Grow

Insufficient new directors

NervGen Pharma Corp. Approves Board and Audit Committee Elections

New minor risk - Market cap size

New major risk - Negative shareholders equity

CEO, President & Director recently bought CA$338k worth of stock

NervGen Pharma Corp., Annual General Meeting, Jun 04, 2024

New minor risk - Market cap size

Independent Director exercised options to buy CA$272k worth of stock.

Co-Founder & Independent Director exercised options to buy CA$347k worth of stock.

New minor risk - Share price stability

Is NervGen Pharma (CVE:NGEN) In A Good Position To Invest In Growth?

NervGen Pharma Corp. Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury

Nervgen Pharma Appoints John Ruffolo to Board of Directors

NervGen Pharma Corp. Announces First Subject Dosed in Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury

Here's Why We're Watching NervGen Pharma's (CVE:NGEN) Cash Burn Situation

Price target increased by 8.6% to CA$6.00

Will NervGen Pharma (CVE:NGEN) Spend Its Cash Wisely?

NervGen Pharma Announces Completion of Dosing of All Subjects in Phase 1 Clinical Trial of Proprietary Drug Candidate NVG-291

NervGen Pharma Corp. (CVE:NGEN) Shares Could Be 31% Below Their Intrinsic Value Estimate

We're Keeping An Eye On NervGen Pharma's (CVE:NGEN) Cash Burn Rate

High number of new and inexperienced directors

Nervgen Pharma Corp. Receives FDA Authorization to Expand Enrollment of Males and Premenopausal Females in Phase 1 Clinical Trial of NervGen's NVG-291

NervGen Pharma Corp. Receives Up to $1.5 Million US Department of Defense Funding to Evaluate NervGen's NVG-291-R for Peripheral Nerve Injury

NervGen Pharma Corp. Announces Executive Changes

NervGen Pharma Corp., Annual General Meeting, Sep 28, 2022

NervGen Pharma Corp. announced that it has received $15.225 million in funding from PFP Biosciences Holdings

NervGen Pharma Corp. Appoints Adam Rogers to its Board of Directors

NervGen Pharma Corp. announced that it expects to receive $15.225 million in funding

We Think NervGen Pharma (CVE:NGEN) Needs To Drive Business Growth Carefully

Nervgen Pharma Corp. Receives Approval from the Safety Review Committee to Advance to the Third and Highest Dose Cohort in the Multiple Ascending Dose Portion of Phase 1 Clinical Trial of the Company's Proprietary Lead Compound, NVG-291

President exercised options to buy CA$112k worth of stock.

Independent Director exercised options to buy CA$224k worth of stock.

Less than half of directors are independent

NervGen Pharma Corp. Announces Executive Changes

We're Not Very Worried About NervGen Pharma's (CVE:NGEN) Cash Burn Rate

High number of new directors

NervGen Pharma Corp. announced that it has received CAD 2.321075 million in funding

NervGen Pharma Corp. announced that it has received CAD 2.343036 million in funding

NervGen Pharma Corp. has completed a Composite Units Offering in the amount of CAD 5.0375 million.

NervGen Pharma Announces First Subject Dosed in Phase 1 Clinical Trial of NVG-291

We're Keeping An Eye On NervGen Pharma's (CVE:NGEN) Cash Burn Rate

NervGen Pharma Corp. Provides Regulatory Update on Development Program for NVG-291

Nervgen Pharma Adds Alzheimer's Disease Patient Cohort to Its Phase 1 Clinical Trial Program

New 90-day high: CA$2.41

New 90-day high: CA$1.90

New 90-day high: CA$1.85

NervGen Pharma Corp. Appoints Dr. Randall Kaye to the Company's Board of Directors

NervGen Pharma Corp. Provides an Update on NVG-291

New 90-day low: CA$1.43

New 90-day low - CA$1.52

NervGen Pharma Corp. has completed a Composite Units Offering in the amount of CAD 6.45 million.

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age